Ticker Hub
MAZE — AI Analysis & Sentiment
3 recent AI-generated analyses for MAZE. Sentiment and confidence insights updated continuously.
Maze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics successfully priced a $150 million registered offering, which will extend its cash runway into 2029. This capital raise is critic...
Apr 22, 2026Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive Phase 2 data for a lead drug candidate and a robust cash position significantly de-risk Maze Therapeutics, making it an attractive medium-...
Mar 25, 2026Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Positive Phase 2 topline data for MZE829, Maze Therapeutics' lead drug candidate, significantly de-risks its development pathway. This paves the wa...
Mar 25, 2026